Literature DB >> 9427220

Clinical, physiological, and histological features in a kindred with the T3271C melas mutation.

M A Tarnopolsky1, J Maguire, T Myint, D Applegarth, B H Robinson.   

Abstract

The majority of patients with MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes) have an A-->G mutation at nucleotide 3243 in mitochondrial transfer (t)RNA. To date there have only been 10 reported cases of MELAS syndrome in patients with a T-->C mutation at position 3271 of mitochondrial tRNA. Although many of the clinical features are similar between patients with these different mutations, it appears that the age at onset is later for the 3271 mutation. This report provides information from a North American kindred with the 3271 mutation (n = 6 proven; n = 2 probable; n = 3 possible) that adds clinical, physiological, histological, and molecular information to the pool of information on this rare disorder. Many of these features were similar to previous reports of both 3243 and 3271 patients. We conclude that the phenotypic expression of these different mutations are similar, but the age of onset for 3271 patients is later than for 3243 patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427220     DOI: 10.1002/(sici)1097-4598(199801)21:1<25::aid-mus4>3.0.co;2-i

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

1.  Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans.

Authors:  M A Tarnopolsky; G Parise; M J Gibala; T E Graham; J W Rush
Journal:  J Physiol       Date:  2001-06-15       Impact factor: 5.182

Review 2.  Mitochondrial diabetes mellitus.

Authors:  J A Maassen; G M C Janssen; H H J P Lemkes
Journal:  J Endocrinol Invest       Date:  2002-05       Impact factor: 4.256

3.  New Variant of MELAS Syndrome With Executive Dysfunction, Heteroplasmic Point Mutation in the MT-ND4 Gene (m.12015T>C; p.Leu419Pro) and Comorbid Polyglandular Autoimmune Syndrome Type 2.

Authors:  Dominique Endres; Patrick Süß; Simon J Maier; Evelyn Friedel; Kathrin Nickel; Christiane Ziegler; Bernd L Fiebich; Franz X Glocker; Friedrich Stock; Karl Egger; Thomas Lange; Michael Dacko; Nils Venhoff; Daniel Erny; Soroush Doostkam; Katalin Komlosi; Katharina Domschke; Ludger Tebartz van Elst
Journal:  Front Immunol       Date:  2019-03-21       Impact factor: 7.561

Review 4.  Mitochondrial Dysfunction in Diseases, Longevity, and Treatment Resistance: Tuning Mitochondria Function as a Therapeutic Strategy.

Authors:  Kazuo Tomita; Yoshikazu Kuwahara; Kento Igarashi; Mehryar Habibi Roudkenar; Amaneh Mohammadi Roushandeh; Akihiro Kurimasa; Tomoaki Sato
Journal:  Genes (Basel)       Date:  2021-08-29       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.